Regenerative Medicine

MIAMI — September 16, 2026 Longeveron Inc. announced topline results from its Phase 2b ELPIS II clinical trial evaluating...

SALT LAKE CITY, Utah — September 15, 2026 PolarityBio announced that the U.S. Food and Drug Administration (FDA) has...

EDINBURGH and LONDON, UK — September 11, 2026 Resolution Therapeutics Limited announced that the final patient has been treated...

Ness Ziona, Israel, September 3, 2026 Matricelf Ltd., a regenerative medicine company developing personalized engineered tissue therapies, has received...

Houston, Texas, September 1, 2026 FibroBiologics, Inc. has announced the issuance of a new U.S. patent covering a potential...

EDINBURGH, UK & LONDON, UK, Sept. 1, 2026 Resolution Therapeutics Limited has partnered with Blood Centers of America, Inc....

Florham Park, New Jersey & Singapore – August 28, 2026 Celularity Inc. announced a new U.S.-based manufacturing collaboration with...

Houston, Texas, August 20, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing regenerative therapies based on fibroblast cells and...

FRANKLIN, Tenn., August 18, 2026 Lynch Regenerative Medicine (LRM) announced the completion of enrollment in an investigator-initiated Phase II...

HOUSTON, August 18, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing therapies based on fibroblast cells and fibroblast-derived materials,...